In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis.
Aerosolized evaporative precipitation into aqueous solution and spray freezing into liquid nanostructured formulations of itraconazole as prophylaxis significantly improved survival relative to commercial itraconazole oral solution and the control in a murine model of invasive pulmonary aspergillosis. Aerosolized administration of nanostructured formulations also achieved high lung tissue concentrations while limiting systemic exposure.
University of Texas Health at Austin College of Pharmacy, TX, USA.
Barbara J
BJ
Hoeben
David S
DS
Burgess
Jason T
JT
McConville
Laura K
LK
Najvar
Robert L
RL
Talbert
Jay I
JI
Peters
Nathan P
NP
Wiederhold
Bradi L
BL
Frei
John R
JR
Graybill
Rosie
R
Bocanegra
Kirk A
KA
Overhoff
Prapasri
P
Sinswat
Keith P
KP
Johnston
Robert O
RO
Williams
D000336:Aerosols; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage*; D001228:Aspergillosis / Q000517:prevention & control*; D002626:Chemistry, Pharmaceutical; D017964:Itraconazole / Q000008:administration & dosage* / Q000097:blood; D008172:Lung Diseases, Fungal / Q000517:prevention & control*; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D049329:Nanostructures
D000336:Aerosols; D000935:Antifungal Agents; D017964:Itraconazole